logo

For the Inventor, By the Inventor

Worcester, MA, United States of America

Metro International Biotech, LLC

Calculating rank
USPTO Granted Patents = 21



Forward Citations = 123

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal David J Livingston (14 out of 17 patents)

silverMedal Jonathan N Kremsky (10 out of 11 patents)

bronzeMedal Bruce G Szczepankiewicz (9 out of 15 patents)

4.  James M McKearin (8 out of 9 patents)

5.  Karl D Normington (7 out of 7 patents)

6.  David Andrew Sinclair (7 out of 33 patents)

7.  Andrew Carr (5 out of 22 patents)

8.  Philippe Fernandes (5 out of 11 patents)

9.  Karen Lavery (4 out of 4 patents)

10.  Matthew Baevsky (3 out of 3 patents)

11.  Bruce Szczpankiewicz (2 out of 2 patents)

12.  Martin Bates (2 out of 2 patents)

13.  Mateusz Pitak (2 out of 5 patents)

14.  Joseph Harris (2 out of 2 patents)

15.  Karsten Koppetsch (2 out of 2 patents)


21 patents:

1. 12767684 - Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide (2026-10-20),
2. 12516081 - Anti-viral compounds and methods of use (2026-01-06),
3. 12485135 - Nicotinamide mononucleotide derivatives and their uses (2025-12-02),
4. 12391721 - Crystal forms of beta-nicotinamide mononucleotide (2025-08-19),
5. 11957703 - Modulating Nudix homology domain (NHD) with nicotinamide mononucleotide analogs and derivatives of same (2024-04-16),
6. 11952396 - Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use (2024-04-09),
7. 11939348 - Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide (2024-03-26),
8. 11878994 - Compositions for treatment of inflammation (2024-01-23),
9. 11878027 - Nicotinamide mononucleotide derivatives and their uses (2024-01-23),
10. 11787830 - Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use (2023-10-17),
11. 11464796 - Nicotinamide mononucleotide derivatives and their uses (2022-10-11),
12. 11279727 - Anti-viral compounds and methods of use (2022-03-22),
13. 11180521 - Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof (2021-11-23),
14. 11059847 - Crystal forms of β-nicotinamide mononucleotide (2021-07-13),
15. 10618927 - Compositions and methods for modulation of nicotinamide adenine dinucleotide (2020-04-14),
Company Overview
Metro International Biotech, LLC is a biotechnology company based in Worcester, MA, specializing in the development and manufacturing of innovative biopharmaceutical products. The organization focuses on advancing therapeutic solutions through cutting-edge research in areas such as drug formulation and delivery systems. With a commitment to improving patient outcomes, Metro International Biotech leverages its expertise to address unmet medical needs, contributing to the evolving landscape of healthcare and biomedicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

21 Patents

#17 in Worcester, MA

#946 in Massachusetts

#15,719 in US

#30,018 in the World

Worcester, MA (US)
Worcester, MA, United States of America

Metro International Biotech, LLC

Forward Citations = 123

21 inventors:

goldMedal David J Livingston (14 out of 17 patents)

silverMedal Jonathan N Kremsky (10 out of 11 patents)

bronzeMedal Bruce G Szczepankiewicz (9 out of 15 patents)

4.  James M McKearin (8 out of 9 patents)

5.  Karl D Normington (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Metro International Biotech, LLC. Retrieved from https://idiyas.com/company/metro-international-biotech

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…